Overview

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Status:
RECRUITING
Trial end date:
2026-03-27
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Phase:
PHASE3
Details
Lead Sponsor:
MoonLake Immunotherapeutics AG
Treatments:
sonelokimab